ReviewNeural regeneration research2023
FcRn inhibitors: a novel option for the treatment of myasthenia gravis.
Review in Neural regeneration research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis.Journal of translational medicine · 2024Pooled it
- The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis.Journal of neurology · 2024Pooled it
- Pooled it
- Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.Journal of neuromuscular diseases · 2025Trial
- Comparative Efficacy of Rozanolixizumab with Efgartigimod or Intravenous Immunoglobulin in Generalized Myasthenia Gravis Using Matching Adjusted Indirect Comparisons.Neurology and therapy · 2026Article
- Efficacy and Safety of Nipocalimab in Adults With Generalised Myasthenia Gravis: An Asian Subgroup Analysis of the Vivacity-MG3 Study.Journal of clinical neurology (Seoul, Korea) · 2026Article
- Interferon regulatory factor 1 enhances T cell differentiation in patients with myasthenia gravis.Neural regeneration research · 2026Article
- B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.Life (Basel, Switzerland) · 2026Review
- Analytical Validation of an ELISA Assay for Maternal Autoantibody-Related Autism.Diagnostics (Basel, Switzerland) · 2026Article
- Comprehensive review on myasthenia gravis: patho-physiology, diagnosis, management strategies.Wiener medizinische Wochenschrift (1946) · 2026Review
- Current GMP standards for the large-scale production of monoclonal antibodies.Bioengineering & translational medicine · 2026Review
- Efgartigimod as Rescue Therapy for PD-1 Inhibitor-Associated Myasthenia Gravis, Myocarditis, and Myositis (MMM) Syndrome: A 2-Case Report and Literature Review.The American journal of case reports · 2026Review
- The role and mechanism of IL‑35 in myasthenia gravis (Review).International journal of molecular medicine · 2026Review
- Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.Annals of clinical and translational neurology · 2026Article
- Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.European journal of neurology · 2026Review
- Review
- MuSK myasthenia gravis: from antigen-antibody to clinical translation.Frontiers in immunology · 2026Review
- Myasthenia gravis with dysphagia as the first symptom and misdiagnosed as anxiety-depressive state: a case report.Frontiers in immunology · 2026Article
- Long-term use of rozanolixizumab in generalised myasthenia gravis: final pooled analysis of the phase III MycarinG study and two open-label extensions.Therapeutic advances in neurological disorders · 2026Article
- Antibody glycosylation in neuroimmune diseases.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis is an acquired, humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction. The intervention-mediated clearance of immunoglobulin G (IgG) was shown to be effective in controlling the progression of the disease. The neonatal Fc receptor (FcRn) plays a key role in prolonging the serum half-life of IgG. Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter, resulting in decreased levels of IgG, including pathogenic autoantibodies, thereby achieving a therapeutic effect. In this review, we detail the substantial research progress, both basic and clinical, relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.